Pancreatic cancer was long considered one of medicine’s deadliest diagnoses. But today, the FDA approved @RevMedicines' Daraxonrasib - a new treatment that has in trials nearly doubled how long patients survive compared to standard chemotherapy. Daraxonrasib works by targeting a molecule, KRAS, that until now was considered undruggable. The story is a reflection of biotech at its best - pioneering what was once believed impossible, persevering through booms and busts, bringing together enabling research, academic labs, and industry to create breakthroughs for patients and their families.  The FDA deserves our commendation for approving this life-changing treatment with the urgency it demanded, and for moving quickly to allow patients to begin accessing it even before formal approval. Who can say how many lives have been extended - how many more birthdays and weddings and anniversaries will be celebrated - thanks to this wonder of science. Here’s to continuing the momentum on revolutionary new treatments for cancer.